BCL2 and B-cell chronic lymphocytic leukemia: Interestingly, the authors concluded that treatment of B-CLL cells with TSA did not alter the expression of other antiapoptotic molecules such as Bcl-2, nor did it increase expression levels of TRAIL-R1 and TRAIL-R2.